San Francisco startup Structure Therapeutics can also be engaged on an oral, once-daily GLP-one drug identified as GSBR-1290—the drug surpassed Wall Street’s anticipations in June every time a mid-phase study confirmed regular weight loss of around six% and it strategies to get start